Targeting Solid Tumors with Off-The-Shelf CAR T Therapies

Wee Kiat Tan, chief operating officer of CytoMed, discusses the company’s platform technology for off-the-shelf CAR T therapies, the advantages they provide over existing autologous CAR T therapies, and why he believes they will be successful at treating solid tumors.

Om Podcasten

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.